Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: A follow-on study to a randomized clinical trial

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: A follow-on study to a randomized clinical trial

Show other versions (1)

Background: In a previous study, 60 infants receiving an investigational serogroup B meningococcal vaccine containing recombinant meningococcal proteins alone (rMenB) or combined with an outer membrane vesicle from Neisseria meningitidis (4CMenB) at 6, 8 and 12 months of age produced serum bacterici...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Snape, MD, Philip, J, John, T, Robinson, H, Kelly, S, Gossger, N, Yu, L, Kittel, C, Toneatto, D, Dull, P, Pollard, A
Formato:	Journal article
Idioma:	English
Publicado em:	2013

Registos relacionados

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
Por: Snape, MD, et al.
Publicado em: (2013)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
Por: Snape, M, et al.
Publicado em: (2013)

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.
Por: Snape, MD, et al.
Publicado em: (2013)

Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.
Por: McQuaid, F, et al.
Publicado em: (2014)

Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age
Por: Snape, M, et al.
Publicado em: (2015)

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.
Por: McQuaid, F, et al.
Publicado em: (2015)

Will booster doses be required for serogroup B meningococcal vaccine?
Por: McQuaid, F, et al.
Publicado em: (2014)

Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.
Por: Snape, MD, et al.
Publicado em: (2006)

Serogroup c meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
Por: Snape, M, et al.
Publicado em: (2006)

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
Por: Gossger, N, et al.
Publicado em: (2012)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
Por: De Whalley, P, et al.
Publicado em: (2013)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
Por: de Whalley, P, et al.
Publicado em: (2013)

Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.
Por: Snape, MD, et al.
Publicado em: (2005)

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
Por: Pace, D, et al.
Publicado em: (2015)

Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
Por: Pollard, A, et al.
Publicado em: (2013)

Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
Por: Snape, MD, et al.
Publicado em: (2010)

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
Por: Iro, M, et al.
Publicado em: (2016)

Emerging experience with meningococcal serogroup B protein vaccines
Por: Daniela Toneatto, et al.
Publicado em: (2017-05-01)

Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].
Por: Iro, M, et al.
Publicado em: (2017)

Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.
Por: Khatami, A, et al.
Publicado em: (2011)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine
Por: Blanchard-Rohner, G, et al.
Publicado em: (2012)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
Por: Blanchard-Rohner, G, et al.
Publicado em: (2012)

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
Por: Snape, MD, et al.
Publicado em: (2009)

Serogroup B meningococcal vaccines-an unfinished story.
Por: Sadarangani, M, et al.
Publicado em: (2010)

Meningococcal serogroup A, C, W, and Y serum bactericidal antibody profiles in Hajj pilgrims
Por: Ziad A. Memish, et al.
Publicado em: (2014-11-01)

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply
Por: Snape, MD, et al.
Publicado em: (2006)

Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years.
Por: McVernon, J, et al.
Publicado em: (2003)

Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy
Por: Arianna Neri, et al.
Publicado em: (2022-05-01)

Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.
Por: Khatami, A, et al.
Publicado em: (2011)

Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses – results from two phase 2b randomized trials in adolescents
Por: Timo Vesikari, et al.
Publicado em: (2021-11-01)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
Por: Read, R, et al.
Publicado em: (2014)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial
Por: Read, R, et al.
Publicado em: (2014)

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Por: Perrett, K, et al.
Publicado em: (2009)

Meningococcal disease serogroup C
Por: Cuevas IE, et al.
Publicado em: (2012-03-01)

Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults
Por: Jessica Presa, et al.
Publicado em: (2023-01-01)

CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.
Por: Kelly, D, et al.
Publicado em: (2006)

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine
Por: De Whalley, P, et al.
Publicado em: (2011)

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
Por: de Whalley, P, et al.
Publicado em: (2011)

Challenges and progress in the development of a serogroup B meningococcal vaccine.
Por: Lewis, S, et al.
Publicado em: (2009)

Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
Por: Perrett, K, et al.
Publicado em: (2010)